Separation and identification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and fast atom bombardment mass spectrometry: choice of complexing agent and application to biological fluids.

[1]  S. De Virgiliis,et al.  Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia. , 1988, Archives of disease in childhood.

[2]  H. Jenny,et al.  Determination of desferrioxamine B, its complexes with iron and aluminium and selected derivatives by high-performance liquid chromatography using a polymer column. , 1988, Journal of chromatography.

[3]  D. McLachlan,et al.  High-performance liquid chromatographic analysis of desferrioxamine. Pharmacokinetic and metabolic studies. , 1988, Journal of chromatography.

[4]  D. Chaleil,et al.  Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis. , 1987, British journal of clinical pharmacology.

[5]  Y. Rahman,et al.  High-performance liquid chromatographic analysis of desferrioxamine using a metal-free system. , 1987, Journal of chromatography.

[6]  P. Houzé,et al.  Quantification of desferrioxamine in blood plasma by inductively coupled plasma atomic emission spectrometry. , 1987, Clinical chemistry.

[7]  E. Chew,et al.  Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. , 1986, The New England journal of medicine.

[8]  P. de Goede,et al.  Determination of desferoxamine and ferrioxamine by high-performance liquid chromatography with direct serum injection and pre-column enrichment. , 1986, Journal of chromatography.

[9]  D. McLachlan,et al.  Determination of desferoxamine and a major metabolite by high-performance liquid chromatography. Application to the treatment of aluminium-related disorders. , 1985, Journal of chromatography.

[10]  S. Cramer,et al.  High-performance liquid chromatography of deferoxamine and ferrioxamine: interference by iron present in the chromatographic system. , 1984, Journal of chromatography.

[11]  P. Barré,et al.  EFFECT OF DESFERRIOXAMINE ON REMOVAL OF ALUMINIUM AND IRON BY COATED CHARCOAL HAEMOPERFUSION AND HAEMODIALYSIS , 1983, The Lancet.

[12]  J. Day,et al.  SUCCESSFUL REMOVAL OF ALUMINIUM FROM PATIENT WITH DIALYSIS ENCEPHALOPATHY , 1980, The Lancet.

[13]  A. Jacobs,et al.  Studies in Desferrioxamine and Ferrioxamine Metabolism in Normal and Iron‐Loaded Subjects , 1979, British journal of haematology.

[14]  W. Anderson,et al.  Continuous Subcutaneous Administration of Deferoxamine in Patients with Iron Overload , 1977 .

[15]  A. Hoffbrand,et al.  SUBCUTANEOUS INFUSION AND INTRAMUSCULAR INJECTION OF DESFERRIOXAMINE IN PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD , 1976, The Lancet.

[16]  A. Shepherd,et al.  The effect of desferrioxamine on the colorimetric determination of iron in human serum and plasma. , 1975, Clinica chimica acta; international journal of clinical chemistry.

[17]  C. B. Modell,et al.  LONG‐TERM DESFERRIOXAMINE THERAPY IN THALASSEMIA , 1974, Annals of the New York Academy of Sciences.

[18]  L. Henderson,et al.  Retention of the α-nitrogen in the metabolic converson of l-lysine to α-aminoadipate by the rat , 1970 .

[19]  H. Keberle,et al.  The metabolism of desferrioxamine B and ferrioxamine B. , 1967, Biochemical pharmacology.

[20]  D. Mattingly,et al.  HOW MANY LADDERS? , 1964, Lancet.

[21]  H. Keberle.  The Biochemistry of Desferrioxamine and its Relation to Iron Metabolism , 1964, Annals of the New York Academy of Sciences.

[22]  Smith Rs.  Iron Excretion in Thalassaemia Major After Administration of Chelating Agents , 1962 .